Inhibitors of Akt activity
View Patent ↗The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention
1. A compound of the formula A:
wherein
R 1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:
a) halogen;
b) C 1-4 alkyl;
c) C 1-4 alkoxy;
d) cyano;
e) di(C 1-4 alkyl)amino;
f) hydroxy;
R 2 represents amino-C 1-6 alkyl, C 1-4 alkylamino-(C 1-6 )alkyl, di(C 1-4 alkyl)amino-(C 1-6 )alkyl;
R 3 represents hydrogen or C 1-6 alkyl; and
R 4 independently represents hydrogen, C 1-6 -alkyl, halogen, HO— or C 1-6 alkyl-O;
r is 0, 1 or 2;
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound according to claim 1 which is:
2,2,N,N-tetramethyl-N-(3-phenyl-[1,2,4]triazolo[3,4-α]phthalazin-6-yl)-propane-1,3-diamine
N′-[3-(4-Methoxy-phenyl)-[1,2,4]triazolo[4,3-α]phthalazin-6-yl)-2,2,N,N-tetramethyl-propane-1,3-diamine
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 1 .
4. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 2 .
5. A pharmaceutical composition made by combining the compound of claim 1 and a pharmaceutically acceptable carrier.
6. A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.